All News     |   Press Releases     |   Newsletters     |   Blog

News

Read all of the latest news, press releases, newsletters, and blog posts. Choose a link above to filter by category.

    • 29 AUG 17
    • 0

    LATTICE BIOLOGICS LTD. REPORTS THIRD QUARTER 2017 HIGHLIGHTS

    First profitable quarter of $.02 per share August 29, 2017 – Belgrade, MT – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces financial results for the third quarter ended June 30, 2017: Highlights: Grenville Strategic Royalty debt restructuring significantly strengthens balance sheet Total liabilities decrease by $2.8 million for nine months ended

    Read more →
    • 17 JUL 17
    • 0

    LATTICE BIOLOGICS LTD. COMPLETES DEBT TO EQUITY CONVERSION AND ISSUES SHARES FOR SERVICES

    July 17, 2017 02:00 PM Mountain Daylight Time BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) is pleased to announce that it has completed the debt-to-equity conversion announced on March 20, 2017 (the “Transaction”). Pursuant to the Transaction, the Company has issued 491,363 common shares (“Shares”) and 491,363 warrants to a service

    Read more →
    • 06 JUL 17
    • 0

    LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE IN DIRECTOR AND CHAIRMAN OF SCIENTIFIC ADVISORY BOARD

    July 06, 2017 02:00 PM Mountain Daylight Time BELGRADE, Mont.–(BUSINESS WIRE)–Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a change in its Board of Directors and appointment of Chairman of the Scientific Advisory Board. After a successful annual general and special meeting (AGM), and a nomination to the Board of Directors

    Read more →
    • 26 JUN 17
    • 0

    LATTICE BIOLOGICS LTD. ANNOUNCES MOVE TO BELGRADE, MT

    June 26, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company”) announces a relocation of its processing facilities to Belgrade, MT. The relocation allows the Company to save over $80,000 per month in rents, overhead, wages, and utilities. The new facility will enable the Company to focus

    Read more →
    • 20 JUN 17
    • 0

    LATTICE BIOLOGICS LTD. ANNOUNCES CHANGE TO LOCATION OF ITS ANNUAL GENERAL AND SPECIAL MEETING

    June 20, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company“) announces that due to increased shareholder interest it is changing the location of its Annual General and Special Meeting to accommodate greater attendance. The time and date of the meeting are unchanged. The meeting will now be held

    Read more →
    • 13 JUN 17
    • 0

    LATTICE BIOLOGICS LTD. ANNOUNCES COMPLETION OF TRANSACTION TO REDUCE ROYALTY AND DEBT OBLIGATIONS

    June 13, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company“) announced today that it has completed the previously announced transaction to significantly reduce the Company’s royalty and debt obligations (the “Transaction“) with Grenville Royalty Corp. (“Grenville“). Pursuant to the Transaction, US$2.7 million of debt was converted into

    Read more →
    • 01 JUN 17
    • 0

    LATTICE BIOLOGICS LTD. RECEIVES MULTI-YEAR AMERICAN ASSOCIATION OF TISSUE BANKS RE-ACCREDITATION

    Accreditation Demonstrates Commitment to Highest Standards for Patients and the Medical Community June 1, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (“Lattice Biologics” or the “Company“) is pleased to announce that it has been approved for re-accreditation by the American Association of Tissue Banks (“AATB“) for processing, storage, and distribution of

    Read more →
    • 31 MAY 17
    • 0

    LATTICE BIOLOGICS LTD. APPOINTS CHIEF OPERATING OFFICER

    May 31, 2017 – Scottsdale, AZ – Lattice Biologics Ltd. (TSX-V: LBL) (OTCQB: LBLTF) (the “Company“) is pleased to announce the appointment of Darrel Holmes as Chief Operating Officer of the Company, effective May 30, 2017. Mr. Holmes is a seasoned executive with over 30 years of experience in the medical device manufacturing and tissue banking

    Read more →

Recent Events